Magnacor Therapeutics’ team has led pioneering research demonstrating the role of microbial infections in atherosclerotic plaques as a critical factor in ischemic events. Supported by funding from the NIH/NHLBI and the American Heart Association, our work leverages advanced microbiology, genomics, and immunology techniques.
We were the first to:
- Demonstrate vascular cell transmission of bacterial pathogens.
- Show associations between dormant bacteria and atheromatous tissues.
- Coin the term “atherosclerosis microbiome” to denote critical microbial communities impacting heart disease.
Our founder, Dr. Kozarov, has collaborated closely with top U.S. research institutions to advance this field. This expertise positions us to advance our platform technology successfully and bring patient-specific therapies to market.
George Dimov
BOD Member
George Dimov is the BOD Member of Magnacor Therapeutics bringing over 20 years of financial and strategic expertise. Known for his skill in driving growth through tailored financial strategies, George’s background spans complex tax planning, mergers and acquisitions, and financial audits. His commitment to operational excellence and strategic planning has positioned Magnacor Therapeutics as a trusted partner for businesses seeking to navigate financial challenges and maximize profitability.
Emil Kozarov
Chairman
Emil Kozarov, MS, PhD is an accomplished biopharmaceutical and biomedical expert with over two decades of experience in both academic and industry settings. Currently the Chairman at Magnacor Inc., he provides strategic consulting, focusing on business development and biopharmaceutical advancements. He was also the Founder and a Visiting Professor at the UNESCO Centre for Biomedical Training and Research in Barcelona. With a background in faculty roles at prestigious institutions such as Columbia University Medical Center and the University of Florida, Emil’s expertise spans anaerobic microbiology, vascular cell biology, and cutting-edge antiatherogenic research.
Vadim Mett
CSO
Vadim Mett is a seasoned biopharmaceutical expert and the Chief Scientific Officer (CSO) at Magnacor Inc. He has extensive experience in vector engineering and immunotherapy, holding senior leadership roles at KBio, Inc., Buffalo BioLabs, and Everon Biosciences. Vadim’s background also includes serving as Chief Scientist at Fraunhofer USA and Research Assistant Professor at Thomas Jefferson University. With over 30 years in the field, Vadim’s expertise spans molecular biotechnology, immunotherapy research, and vaccine development, contributing to advancements in biomedicine.
Gaurav Vij (Vik)
CEO & Board Member
Gaurav Vij is a disciplined and results-driven biopharmaceutical executive with extensive experience in corporate development, strategic growth, and commercial operations across a broad range of therapeutic areas, including oncology, cell therapy, ophthalmology, and rare diseases. He has a proven track record of sourcing, negotiating, and closing complex domestic and international M&A and licensing transactions from inception through completion.
Frequently Asked Question
What is the focus of Magnacor Therapeutics’ research?
Magnacor is dedicated to developing a novel class of drugs that target atherosclerosis and other chronic inflammatory diseases. Our research specifically addresses cardiovascular disease, aiming to provide therapies for patients with critical unmet medical needs.
What stage is Magnacor Therapeutics in its research and development process?
We have successfully completed animal trials that showed promising results in reducing atherosclerotic plaques. Currently, we are preparing for human trials to further test our therapies with the goal of bringing life-changing treatments to patients worldwide.
How is your approach to cardiovascular disease treatment different?
Our approach focuses on addressing bacterial pathogens associated with atherosclerotic plaques, a factor largely overlooked in traditional treatments. By targeting these intracellular pathogens, we aim to reduce inflammation and atherosclerotic plaque formation, providing a more comprehensive solution to cardiovascular disease.
How can I get involved with Magnacor Therapeutics’ mission?
We welcome interest from potential investors, collaborators, and partners who are passionate about advancing cardiovascular care. Reach out via our Contact Us page to explore opportunities for investment, licensing, or collaboration.